Last reviewed · How we verify
NCT06314828
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
Phase 1 trial testing RJMty19 (CD19-CAR-DNT cells) in B-cell Non-Hodgkin's Lymphoma in 30 participants. Not yet recruiting.
20 May 2025
Quick facts
| Lead sponsor | Guangdong Ruishun Biotech Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 20 May 2024 |
| Primary completion | 20 May 2025 |
| Estimated completion | 20 May 2027 |
Drugs / interventions tested
- RJMty19 (CD19-CAR-DNT cells) — full drug profile →
Conditions studied
- B-cell Non-Hodgkin's Lymphoma — all drugs for B-cell Non-Hodgkin's Lymphoma →
Sponsor
Guangdong Ruishun Biotech Co., Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with B-cell Non-Hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR immunotherapy in autoimmune diseases: promises and challenges.
Yu J, Yang Y, Gu Z, Shi M, et al · · 2024 · cited 13× · PMID 39411714 · DOI 10.3389/fimmu.2024.1461102 -
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108 -
A preclinical study of allogeneic CD19 chimeric antigen receptor double-negative T cells as an off-the-shelf immunotherapy drug against B-cell malignancies.
Wang D, Wang L, Liu S, Tong J, et al · · 2024 · cited 1× · PMID 39720695 · DOI 10.1002/cti2.70022
Verify or expand the search:
- PubMed search for NCT06314828
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RJMty19 (CD19-CAR-DNT cells)
Trials testing the same drug.
- NCT06340490 — A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) · Phase 1 · not yet recruiting
Other recruiting trials for B-cell Non-Hodgkin's Lymphoma
Currently open trials in the same condition.
- NCT07081022 — JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting
- NCT05436223 — Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting
Other Guangdong Ruishun Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT06894693 — A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies · Phase 1 · not yet recruiting
- NCT06340490 — A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) · Phase 1 · not yet recruiting
- NCT05858814 — RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT · Phase 1, PHASE2 · recruiting
- NCT05471323 — Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06314828 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Ruishun Biotech Co., Ltd
- Last refreshed: 18 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06314828.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing